drugset / Trial / NCT02359045

Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions

NCT02359045

Phase 1 Completed 137 enrolled AstraZeneca
RandomizedCrossoverOpen-labelBasic science

Summary

This study is a randomized, open-label, cross-over study in healthy subjects performed at a single study center. The study is divided into two parts, Part 1 and Part 2. The purpose of the study is to compare the pharmacokinetics (PK) of three different prototype capsule formulations (omega-3-carboxylic acids test formulations) with Epanova® capsules 1000 mg under fasted conditions in Part 1 and under fed conditions in Part 2. The results will be used as basis for choice of formulation for further pharmaceutical development.

Timeline

Start
2015-02-12
Primary completion
2015-07-27
Completion
2015-07-27

Drugs

EvaluationDrugModalityDoseRoute
Subject D14000136 Unknown 2000 mg
Subject D14000137 Unknown 2000 mg
Subject D1400147 Unknown 2000 mg
Subject Epanova Other / unclassified 1000 mg

Indications

No indication recorded.